News
We are hiring – Technical Writer
Are you an experienced Technical Writer with a critical thinking mindset and an eye for details? Do you have experience from the Medtech or Pharmaceutical
Devyser receives MDSAP certification
We’re happy to announce that we’ve received certification for the successful completion of a Quality Management System audit under the Medical Device Single Audit Program
Case Study – A new NGS-based method for chimerism monitoring
New methods for mixed chimerism analytics are transforming post-transplant monitoring, enabling earlier detection of relapse and initiation of treatment to improve and save the lives
Major health care providers in Latin America implement Devyser’s solutions to improve post-transplant healthcare management
IMSS, Mexico’s largest public health care provider and INP, Mexico’s National Institute of Pediatrics, now use Devyser’s solutions for chimerism monitoring of transplanted patients Stockholm
Cancer doesn’t take a break, neither do we
We’re shipping! While the world focused on Covid-19 testing, cancer did not take a break. We’re so relieved that priorities are now diversifying to include
Devyser at DGTI 2020
Come and visit our virtual booth at DGTI! The 53rd annual meeting in Immunohaematology and Transfusion Medicine is taking place virtually from September 16th to
Devyser welcomes Fredrik Alpsten as new CEO
Devyser welcomes Fredrik Alpsten as new CEO starting September 1st. Ulf Klangby, the former CEO and founder of Devyser, continues as COO and board member
Devyser’s breakthrough NGS product for hereditary breast and ovarian cancer testing now approved for diagnostic use in the EU
Stockholm, 22 July 2020 —Swedish genetic test developer Devyser’s product for hereditary breast and ovarian cancer (HBOC) is now CE labelled and approved for diagnostic
Discover Devyser CFTR 68
https://vimeo.com/434385139/77bd5832b6 Discover Devyser CFTR 68, our latest kit for the analysis of the CFTR gene, capable of detecting up to 68 mutations most commonly associated